November 10, 2025
 
 
RedChip Logo
Small Stocks, Big Money™
Weekly Newsletter
REDCHIP.COM
 
Feature News
 
NioCorp Hits High-Grade Rare Earths and Niobium in Second Elk Creek Drill Hole
 
NioCorp (Nasdaq: NB) has delivered another strong set of assay results from its Elk Creek Project in Nebraska, with the second diamond drill hole intersecting 733.42 meters of mineralized carbonatite and several higher-than-expected grades, including up to 1.28% Nb₂O₅ and 6,017 ppm TREO. The results reinforce the continuity and quality of the resource as the company works to upgrade portions of its mineral inventory from Indicated to Measured, supporting future reserve conversions.
 
 
 
 
 
 
 
 
 
ASP Isotopes' Subsidiary QLE Raises $64.3M in Convertible Note Deal Backed by Trump Brothers
 
Quantum Leap Energy LLC, a wholly-owned subsidiary of ASP Isotopes Inc. (Nasdaq: ASPI), has secured $64.3 million in a private placement of convertible notes, led by American Ventures LLC with strategic backing from Eric Trump and Donald Trump Jr. The funding will accelerate the development of QLE’s laser isotope enrichment facilities, advancing ASP Isotopes' mission to supply critical isotopes for quantum computing, healthcare, and green energy applications.
 
 
 
 
 
 
 
BullFrog AI's Breakthrough Pancreatic Cancer Study Accepted at ASCO GI 2026 – Major Validation of Its AI Drug Development Platform
 
BullFrog AI (Nasdaq: BFRG) is gaining major momentum with the acceptance of its AI-powered study at the prestigious 2026 ASCO GI Cancers Symposium. In collaboration with Eleison Pharmaceuticals, the abstract showcases how BullFrog’s bfLEAP® and bfPREP™ platforms identified patient subtypes potentially more responsive to glufosfamide, a pancreatic cancer therapy. With publication in the Journal of Clinical Oncology forthcoming, this milestone not only validates BullFrog’s precision-oncology tech but sets the stage for accelerated commercial traction.
 
 
 
 
 
 
 
 
 
Jupiter Neurosciences Clears Key FDA Hurdle to Launch Phase 2a Parkinson’s Trial with JOTROL™
 
Jupiter Neurosciences (Nasdaq: JUNS) has received FDA clearance to initiate a Phase 2a clinical trial of JOTROL™, its proprietary resveratrol-based drug platform, in patients with Parkinson’s disease—a $14B market opportunity by 2030. Backed by strong Phase I safety and bioavailability data, JOTROL’s novel delivery system delivers over 9x higher absorption than traditional resveratrol, positioning it as a potential disease-modifying therapy in a space still lacking one. Patient enrollment is expected to begin in early 2026.
 
 
 
 
 
 
 
Gorilla Technology Taps Infrastructure Veteran Thomas Sennhauser as CTO to Lead $1.4B AI Rollout
 
Gorilla Technology (Nasdaq: GRRR) has appointed enterprise tech leader Thomas Sennhauser as Chief Technology Officer of its Infrastructure Practice, following his pivotal role in the company’s $1.4 billion Freyr sovereign AI initiative across Southeast Asia. With deep experience from Intel and HPE, Sennhauser will now spearhead Gorilla’s global expansion of AI data centers, GPU-as-a-Service platforms, and national-scale digital infrastructure, cementing Gorilla’s leadership in AI-powered transformation at sovereign scale.
 
 
 
 
 
Recent News
 
 
 
 
 
 
 
 
 
 
 
RedChip TV
 
 
 
 
RedChip Highlights Jackpot Digital Inc., FatPipe, Inc. & NDT Pharmaceuticals Inc.
 
 
 
 
 
 
 
RedChat Ad
 
 
Unlock Smarter Investing with RedChat
RedChat Ad
Tired of sifting through endless filings? Let RedChat do the heavy lifting. Get real-time, data-driven insights on over 2,000 small-cap stocks—instantly. Save time, make informed decisions, and stay ahead of the market.
Access RedChat now, free of charge.
START USING REDCHAT
 
Recent Research Coverage Updates
 
Company Rating Price Target Firm Report Date
Nova Minerals (Nasdaq: NVA) Buy $50 ThinkEquity October 27, 2025
NioCorp (Nasdaq: NB) Buy $15 Maxim October 15, 2025
NioCorp (Nasdaq: NB) Buy $8 H.C. Wainwright September 22, 2025
Alliance Entertainment (Nasdaq: AENT) Buy $11 Noble Capital October 6, 2025
FibroBiologics (Nasdaq: FBLG) Buy $4 Maxim September 22, 2025
XORTX Therapeutics (Nasdaq: XRTX) Buy $14 AGP September 18, 2025
FibroBiologics (Nasdaq: FBLG) Buy $10 H.C. Wainwright September 12, 2025
Alliance Entertainment (Nasdaq: AENT) Buy $10 Maxim September 11, 2025
FibroBiologics (Nasdaq: FBLG) Buy $16 D Boral September 10, 2025
Greenwich LifeSciences (Nasdaq: GLSI) Buy $45 Noble August 20, 2025
Nexalin Technology (Nasdaq: NXL) Buy $4 Maxim August 19, 2025
Atossa Therapeutics (Nasdaq: ATOS) Buy $7 HC Waingwright August 12, 2025
Atossa Therapeutics (Nasdaq: ATOS) Buy $4 Maxim August 12, 2025
Atossa Therapeutics (Nasdaq: ATOS) Buy $4 Maxim August 12, 2025
FibroBiologics (Nasdaq: FBLG) Buy $16 D Boral July 29, 2025
Connect Biopharma (Nasdaq: CNTB) Buy $7.5 Northland Securities July 23, 2025
Connect Biopharma (Nasdaq: CNTB) Buy $4 Titan Partners July 17, 2025
NioCorp (Nasdaq: NB) Buy $5 Maxim July 10, 2025
Connect Biopharma (Nasdaq: CNTB) Buy $7 H.C. Wainwright July 9, 2025
FibroBiologics (Nasdaq: FBLG) Buy $16 D Boral July 9, 2025
NioCorp (Nasdaq: NB) Buy $4 HC Wainwright July 2, 2025
Alliance Entertainment (Nasdaq: AENT) Buy $10 Maxim July 1, 2025
 
 
 
Podcast Logo
Small Stocks, Big Money™ Podcast
The podcast features in-depth interviews with CEO's from the top names in small-cap stocks, providing listeners with a unique perspective not found anywhere else.
Available on:
Amazon Music Apple Podcasts Spotify
LEARN MORE
 
 
Upcoming Events
 
 
11
 
 
NOV 2025
 
Bimergen Energy (OTCQB: BESS)
4:15pm Eastern
 
Bimergen Energy Corporation is a publicly traded independent power provider and project developer focused on utility-scale battery energy storage systems (BESS) assets.
 
 
 
 
 
 
 
18
 
 
NOV 2025
 
ProPhase Labs (NASDAQ: PRPH)
04:15pm Eastern
 
ProPhase Labs Inc. (Nasdaq: PRPH) ("ProPhase") is a next-generation biotech, genomics and diagnostics company. Our goal is to create a healthier world with bold action and the power of insight.
 
 
 
 
 
 
 
19
 
 
NOV 2025
 
Calidi Biotherapeutics (NYSE American: CLDI)
4:15pm Eastern
 
RedTail platform precisely delivers genetic medicines to sites of disease, offering solutions from cancer to other complex diseases.
 
 
 
 
 
 
 
Archived Events
 
 
5
 
 
NOV 2025
 
NDT Pharmaceuticals (OTC: NDTP)
4:15pm Eastern
 
NDT Pharmaceuticals is a publicly traded health and wellness company redefining biosafety through its wholly owned subsidiary, Good Salt Life.
 
 
 
 
 
 
 
3
 
 
NOV 2025
 
Connect Biopharma Holdings (NASDAQ: CNTB)
4:15pm Eastern
 
Connect Biopharma, headquartered in San Diego, California, is a clinical-stage biopharmaceutical company focused on advancing Rademikibart™, a potentially best-in-class next generation anti-interleukin-4-receptor alpha (IL-4Rα) antibody, to transform care in Asthma and COPD.
 
 
 
 
 
 
Quote of the Week
 
" You don't learn to walk by following rules. You learn by doing, and by falling over. "
— Sir Richard Branson, Founder of Virgin Group
 
 
Order "Small Stocks, Big Money™ Today!
 
Dave Gentry's new book, Small Stocks, Big Money: Interviews With Microcap Superstars, is now available for pre-order. Published by Wiley Finance, this first-hand perspective and insider information on the fast world of microcap investing is now available for purchase.
 
 
 
 
 
 
 
Lesson of the Week
 
Inefficiencies create opportunities.